Please check your internet connection and try again.
# Arsil-DX
## Overview
Arsil-DX (typically synonymous with **Artemether/Lumefantrine**) is a fixed-dose oral artemisinin-based combination therapy (ACT). It combines a rapid-acting artemisinin derivative (artemether) with a longer-acting partner drug (lumefantrine) to treat uncomplicated malaria while preventing the development of resistance.
## Primary Indications
Treatment of acute, uncomplicated *Plasmodium falciparum* malaria.
## Adult Dosing
Based on a standard 6-dose regimen over 3 days (administered at 0, 8, 24, 36, 48, and 60 hours).
* **Patients ≥35 kg:** 4 tablets (total 80 mg artemether/480 mg lumefantrine) per dose.
* **Total treatment course:** 24 tablets.
## Pediatric Dosing
Dosing is strictly weight-based. Ensure administration with food/fatty drink to optimize absorption.
* **5 kg to <15 kg:** 1 tablet per dose (total 6 doses).
* **15 kg to <25 kg:** 2 tablets per dose (total 6 doses).
* **25 kg to <35 kg:** 3 tablets per dose (total 6 doses).
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal dosage adjustments provided by the manufacturer, but use with caution; monitor for potential accumulation if severe impairment exists.
* **Vomiting:** If the patient vomits within 30 minutes of dose administration, re-dose the full amount.
## Contraindications
* Known hypersensitivity to artemether or lumefantrine.
* Severe or complicated malaria (requires parenteral therapy).
* History of QT prolongation or congenital long QT syndrome.
* Current use of drugs that prolong the QT interval (e.g., flecainide, amiodarone, certain antipsychotics).
## Adverse Effects
* **Common:** Headache, dizziness, anorexia, fatigue, arthralgia, myalgia.
* **Gastrointestinal:** Nausea, vomiting, abdominal pain, diarrhea.
* **Serious:** Potential for QT interval prolongation; allergic reactions (urticaria/angioedema).
## Key Drug Interactions
* **QT Prolonging Agents:** Avoid concurrent use (e.g., macrolides, fluoroquinolones, H1-antagonists).
* **CYP3A4 Inhibitors/Inducers:** Strong inhibitors (e.g., ketoconazole) may increase lumefantrine levels; strong inducers (e.g., rifampin, carbamazepine) may decrease efficacy.
* **Hormonal Contraceptives:** May decrease efficacy; recommend back-up barrier method during treatment.
## Monitoring
* **Cardiac:** Baseline ECG in high-risk patients. Monitor for signs of arrhythmias if symptoms suggest (palpitations, syncope).
* **Efficacy:** Parasite clearance and resolution of fever; monitor for signs of treatment failure (e.g., persistent parasitemia).
## Clinical Pearls
* **Absorption:** Lumefantrine absorption is significantly enhanced by lipids. Administer each dose with food, milk, or a high-fat liquid supplement.
* **Adherence:** Complete the full 6-dose regimen even if symptoms resolve to prevent recrudescence.
* **Uncertainty Note:** Specific weight-based dosing ranges and regional resistance patterns vary significantly per WHO and local Ministry of Health guidelines. Always consult local malaria treatment algorithms for endemic regions.
***
*Disclaimer: This information is for educational purposes only. Clinical guidelines and resistance patterns change frequently. Always verify the most current prescribing information, local drug formularies, and institutional protocols before ordering or administering medication.*
